Panel Headliner Stage track
2026 and BioPharma’s M&A Boom
Mon, Nov 16, 2026 · 10:30–11:15 AM GMT Old Billingsgate
About this session
A fast‑moving M&A cycle is reshaping biopharma in 2026, propelled by patent cliffs and cash‑rich balance sheets. This panel will identify the buyers and platform technologies behind the biggest deals, examine how rapid innovation is recalibrating valuations and acquisition strategy, and unpack the deal structures delivering successful exits—then look ahead to how Big Pharma is positioning for 2027 Evaluating M&A activity in 2026 and how patent cliffs have accelerated biopharma dealmaking Which buyers and biotech platforms are driving the biggest deals? How is rapid innovation reshaping…
